首頁 > 市場調查報告書 > 製藥

生物製劑

蛋白酪氨酸激酶抑制劑市場規模、佔有率及成長分析（按類型、應用、最終用戶、分銷管道和地區）—產業預測，2025 年至 2032 年

市場調查報告書

商品編碼

1758557

蛋白酪氨酸激酶抑制劑市場規模、佔有率及成長分析（按類型、應用、最終用戶、分銷管道和地區）—產業預測，2025 年至 2032 年

Tyrosine Kinase Inhibitors Market Size, Share, and Growth Analysis, By Type, By Application, By End Users, By Region - Industry Forecast 2025-2032

出版日期: 2025年06月19日 | 出版商:

SkyQuest | 英文 193 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球蛋白酪氨酸激酶抑制劑市場規模為 369 億美元，預計將從 2024 年的 390 億美元成長到 2032 年的 607.7 億美元，預測期內（2025-2032 年）的複合年成長率為 5.7%。

蛋白酪氨酸激酶抑制劑 (TKI) 市場正在經歷強勁成長，這得益於需要這些關鍵治療方法的癌症和慢性病發病率上升。 TKI特異性針對參與細胞訊號傳導路徑的酶，對於治療各種癌症（包括肺癌、乳癌和白血病）的個人化醫療至關重要。分子生物學和藥物開發的最新趨勢導致更有效和選擇性的 TKI 的出現，改善了患者的治療效果並擴大了可用治療方法的範圍。針對對抗抗藥性和減少副作用的下一代抑制劑的積極研發工作使市場煥發了活力。然而，高成本和監管障礙等挑戰依然存在。特別是聯合治療和創新藥物輸送系統等趨勢預計將進一步推動市場擴張，以及全球醫療基礎設施的成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Pfizer Inc.（USA）
Novartis AG（Switzerland）
AstraZeneca plc（UK）
Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（USA）
Merck & Co., Inc.（USA）
Eli Lilly and Company（USA）
Bayer AG（Germany）
AbbVie Inc.（USA）
Daiichi Sankyo Company, Limited（Japan）
Takeda Pharmaceutical Company Limited（Japan）
GlaxoSmithKline plc（GSK）（UK）
Johnson & Johnson（USA）
Boehringer Ingelheim International GmbH（Germany）
Exelixis, Inc.（USA）
Incyte Corporation（USA）
Ascentage Pharma（China）

結論和建議

簡介目錄

Product Code: SQMIG35A3039

Global Tyrosine Kinase Inhibitors Market size was valued at USD 36.9 billion in 2023 and is poised to grow from USD 39.0 billion in 2024 to USD 60.77 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The Tyrosine Kinase Inhibitors (TKIs) market is experiencing robust growth, propelled by the rising incidence of cancer and chronic illnesses that necessitate these pivotal therapies. By specifically targeting enzymes involved in cell signaling pathways, TKIs are vital in personalized medicine for treating diverse cancers like lung, breast, and leukemia. Recent advancements in molecular biology and drug development have led to the emergence of more effective, selective TKIs, enhancing patient outcomes and broadening available treatments. The market is bolstered by vigorous R&D efforts aimed at next-generation inhibitors to combat resistance and reduce side effects. However, challenges such as high costs and regulatory hurdles persist. Notably, trends like combination therapies with immunotherapies and innovative drug delivery systems are expected to further drive market expansion alongside growing global healthcare infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tyrosine Kinase Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tyrosine Kinase Inhibitors Market Segments Analysis

Global Tyrosine Kinase Inhibitors Market is segmented by Type, Application, End Users, Distribution Channel and region. Based on Type, the market is segmented into BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and Others. Based on Application, the market is segmented into Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer and Others. Based on End Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors market is primarily propelled by the alarming increase in cancer cases worldwide, especially in prevalent forms like lung cancer, breast cancer, and leukemia. Tyrosine Kinase Inhibitors (TKIs) provide targeted therapeutic strategies by disrupting specific enzymes that contribute to the proliferation of cancer cells, rendering them more effective and desirable alternatives to conventional chemotherapy methods. This rising interest in precision medicine, along with heightened public awareness and advancements in early cancer detection, is considerably widening the patient demographic that stands to benefit from the use of TKIs, further driving market growth.

Restraints in the Global Tyrosine Kinase Inhibitors Market

Although tyrosine kinase inhibitors (TKIs) offer significant clinical advantages, their high costs present a major barrier to accessibility, particularly in developing nations and for uninsured individuals. The overall expense encompasses not only the price of the medications themselves but also the necessary diagnostic tests and continual monitoring, which can put considerable pressure on healthcare systems and impede broad adoption. Financial limitations and challenges related to reimbursement may further stifle market growth, as both payers and healthcare providers look for more cost-effective treatment options. Consequently, these factors can restrict the overall reach and utilization of TKIs in various populations.

Market Trends of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors (TKIs) market is witnessing a significant trend towards the integration of combination therapies with immunotherapy, particularly alongside checkpoint inhibitors. By synergistically enhancing the immune system's tumor-targeting capabilities while simultaneously inhibiting kinase-mediated tumor growth, these innovative treatment regimens are demonstrating enhanced efficacy in early clinical trials, characterized by improved response rates and prolonged progression-free survival. As research in this area expands, the paradigm shift towards these combination approaches is poised to redefine standard oncology treatment protocols, thereby unlocking substantial growth opportunities within the TKIs market and driving an evolution in cancer care strategies globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Tyrosine Kinase Inhibitors Market Size by Type & CAGR (2025-2032)

Market Overview
BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
Others

Global Tyrosine Kinase Inhibitors Market Size by Application & CAGR (2025-2032)

Market Overview
Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Others

Global Tyrosine Kinase Inhibitors Market Size by End Users & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Tyrosine Kinase Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others

Global Tyrosine Kinase Inhibitors Market Size & CAGR (2025-2032)

North America (Type, Application, End Users, Distribution Channel)
- US
- Canada
Europe (Type, Application, End Users, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, End Users, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, End Users, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, End Users, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ascentage Pharma (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments